These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 30271402)

  • 1. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
    Peltzer J; Aletti M; Frescaline N; Busson E; Lataillade JJ; Martinaud C
    Front Immunol; 2018; 9():2013. PubMed ID: 30271402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.
    Yang H; Cheong S; He Y; Lu F
    Stem Cell Res Ther; 2023 Dec; 14(1):372. PubMed ID: 38111001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells for systemic sclerosis treatment.
    Farge D; Loisel S; Lansiaux P; Tarte K
    Autoimmun Rev; 2021 Mar; 20(3):102755. PubMed ID: 33476823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis.
    Maria ATJ; Rozier P; Fonteneau G; Sutra T; Maumus M; Toupet K; Cristol JP; Jorgensen C; Guilpain P; Noël D
    Front Immunol; 2018; 9():3056. PubMed ID: 30622540
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis.
    Zhuang X; Hu X; Zhang S; Li X; Yuan X; Wu Y
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):284-320. PubMed ID: 35031958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?
    Rozier P; Maria A; Goulabchand R; Jorgensen C; Guilpain P; Noël D
    Front Immunol; 2018; 9():2938. PubMed ID: 30619298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis.
    Maria AT; Toupet K; Maumus M; Fonteneau G; Le Quellec A; Jorgensen C; Guilpain P; Noël D
    J Autoimmun; 2016 Jun; 70():31-9. PubMed ID: 27052182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells.
    Maria ATJ; Toupet K; Maumus M; Rozier P; Vozenin MC; Le Quellec A; Jorgensen C; Noël D; Guilpain P
    Front Immunol; 2018; 9():2571. PubMed ID: 30455706
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients.
    Virzì F; Bianca P; Giammona A; Apuzzo T; Di Franco S; Mangiapane LR; Colorito ML; Catalano D; Scavo E; Nicotra A; Benfante A; Pistone G; Caputo V; Dieli F; Pirrello R; Stassi G
    Stem Cell Res Ther; 2017 Oct; 8(1):236. PubMed ID: 29058626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cells therapy: the future in the management of systemic sclerosis? A case report.
    Song JI; Volz S; Liodaki ME; Mailänder P; Kalousis K
    Hell J Nucl Med; 2017; 20 Suppl():164. PubMed ID: 29324934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
    Di Benedetto P; Liakouli V; Ruscitti P; Berardicurti O; Carubbi F; Panzera N; Di Bartolomeo S; Guggino G; Ciccia F; Triolo G; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2018 Oct; 20(1):223. PubMed ID: 30285896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive properties of mesenchymal stem cells: advances and applications.
    De Miguel MP; Fuentes-Julián S; Blázquez-Martínez A; Pascual CY; Aller MA; Arias J; Arnalich-Montiel F
    Curr Mol Med; 2012 Jun; 12(5):574-91. PubMed ID: 22515979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis.
    Maria AT; Toupet K; Bony C; Pirot N; Vozenin MC; Petit B; Roger P; Batteux F; Le Quellec A; Jorgensen C; Noël D; Guilpain P
    Arthritis Rheumatol; 2016 Apr; 68(4):1013-25. PubMed ID: 26474311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis.
    Zhao K; Kong C; Shi N; Jiang J; Li P
    Front Immunol; 2023; 14():1125257. PubMed ID: 37251412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis.
    Del Papa N; Pignataro F; Zaccara E; Maglione W; Minniti A
    Front Immunol; 2018; 9():2390. PubMed ID: 30386340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases].
    Sánchez-Berná I; Santiago-Díaz C; Jiménez-Alonso J
    Med Clin (Barc); 2015 Jan; 144(2):88-91. PubMed ID: 24636281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis.
    Velier M; Daumas A; Simoncini S; Arcani R; Magalon J; Benyamine A; Granel B; Dignat George F; Chabannon C; Sabatier F
    Bone Marrow Transplant; 2022 Jan; 57(1):17-22. PubMed ID: 34663928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular Therapies in Systemic Sclerosis: Recent Progress.
    van Rhijn-Brouwer FC; Gremmels H; Fledderus JO; Radstake TR; Verhaar MC; van Laar JM
    Curr Rheumatol Rep; 2016 Feb; 18(2):12. PubMed ID: 26943351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contribution of mesenchymal stromal cell transplantation in systemic scleroderma].
    Lansiaux P; Farge D
    Rev Prat; 2022 Apr; 72(4):355-362. PubMed ID: 35638974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis.
    Loisel S; Lansiaux P; Rossille D; Ménard C; Dulong J; Monvoisin C; Bescher N; Bézier I; Latour M; Cras A; Farge D; Tarte K
    Stem Cells Transl Med; 2023 Apr; 12(4):194-206. PubMed ID: 36928395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.